A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD)

NCT05596422 | Completed

• 1 other identifier: Vedolizumab-4030
• Study Type: observational
• Target: 423
• Locations: 1 country
• Sites: 4

Brief Summary

This is a non-interventional, retrospective study of adult participants with IBD. IBD consists of either ulcerative colitis (UC) or Crohn's disease (CD). The study will review the clinical data previously collected during February 2007 to March 2020 of approximately 724 participants who have had treatment with adalimumab, infliximab, golimumab, or vedolizumab in Taiwan.

Conditions

Inflammatory Bowel Disease (IBD); Ulcerative Colitis; Crohn's Disease

Keywords

Drug Therapy

Outcome Measures

Primary Outcomes (9)

• Percentage of Participants Who Had IBD Relapse

  IBD Relapse includes re-treatment with biologics, steroid use, IBD-related hospitalization record, IBD-related ER visits, IBD-related surgery, increase in disease index. The occurrence of any of the above records will be regarded as an IBD relapse.

  Up to approximately 13 years

• Time to Relapse After Biologics Discontinuation

  Time to relapse is defined as the time interval from end of treatment (EOT) to the first IBD relapse.

  Up to approximately 13 years

• Correlation Between the Clinical Variables and Relapse Post Biologics Discontinuation

  The identifying predictors of relapse, survival distributions will be studied using the log-rank test for the univariate analysis and then using time dependent Cox regression models for the multivariate analysis. The potential confounders of relapse including demographics, disease status, IBD-related treatment, symptom control treatment, lab and complication will be assessed. Two predictive models will be built in the study, one is "on biologics treatment", and other is "off biologics treatment".

  Up to approximately 13 years

• Percentage of Participants Achieving Clinical Response

  Clinical Response for CD is defined as Crohn's disease active index (CDAI) greater than or equal to (\>=) 70 points reduction from the index date. For UC, Mayo score \>=3 points reduction and \>=30 percent (%) decrease from the index date with an accompanying rectal bleeding subscore \>=1 points reduction or with absolute rectal bleeding subscore less than or equal to (\<=) 1 and as \>=2 point reduction in partial Mayo score. Index date: date when the first dose of the biologic was prescribed in each treatment cycle.

  Up to approximately 13 years

• Percentage of Participants Achieving Clinical Remission

  Clinical Remission for CD is defined as CDAI \<=150 point.CDAI assesses CD based on clinical signs such as number of liquid stools,intensity of abdominal pain,general wellbeing,presence of comorbid conditions,antidiarrheal use,physical examination and laboratory findings.Total score ranges from 0 to 600 points.Clinical Remission for UC is defined as Mayo score \<=2 and no individual subscore \>1 and partial Mayo score \<=1.Mayo score measure disease activity of UC.Mayo score consists of 4 sub-scores: stool pattern,most severe rectal bleeding of the day,endoscopic findings,global assessment by physician,each graded from 0 to 3 with higher scores indicating more severe disease.Scores are summed to give a total score range of 0 to 12.Partial Mayo score consists of 3 sub-scores:stool pattern,most severe rectal bleeding of the day, global assessment by physician, each graded from 0 to 3 with higher scores indicating more severe disease.Scores are summed to give a total score range of 0 to 9.

  Up to approximately 13 years

• Percentage of Participants Achieving Steroid-free Remission

  Steroid-free remission for CD is defined as CDAI \<=150 point. CDAI assesses CD based on clinical signs such as number of liquid stools, intensity of abdominal pain, general wellbeing, presence of comorbid conditions, antidiarrheal use, physical examination and laboratory findings. Total score ranges from 0 to 600 points. Steroid-free remission for UC is defined as absence of steroid treatment (within 1 week before and after the date of potential clinical remission achieved) among participants on steroids at baseline (index date). Index date: date when the first dose of the biologic was prescribed in each treatment cycle.

  Up to approximately 13 years

• Percentage of Participants Achieving Mucosal Healing

  Mucosal healing is defined as absence of any symptom finding of ulcer or spontaneous bleeding on endoscopic assessment or Crohn's Disease Endoscopic Index of Severity (CDEIS) less than (\<) 4 for CD participants and as Mayo endoscopic subscore \<=1 for UC participants.

  Up to approximately 13 years

• Correlation Between the Clinical Variables and Treatment Effectiveness

  The relationship between clinical variables and treatment effectiveness will be assessed. The impact of potential bias from the baseline/demographic variables, baseline matching will be performed using propensity score 1:1 matching by each treatment cycle and different types of biologic treatments before performing the comparative analysis for effectiveness outcome. The matching condition will be determined according to the data collection. IBD participants with clinical response, clinical remission, steroid-free remission, and mucosal healing will be analyzed. The difference in effectiveness between IBD participants receiving different types of biologic treatment will be compared using Chi-square test.

  Up to approximately 13 years

• Percentage of Participants Experiencing Infection

  Participants experiencing opportunistic infections, hepatic viral infections, gastrointestinal (GI) infections, respiratory infections, respiratory failure, or sepsis or septic shock among participants receiving vedolizumab versus those receiving anti-TNF-α will be assessed.

  Up to approximately 13 years

Study Arms (2)

Cohort 1: Participants With Biologics Discontinuation

Participants with IBD (UC or CD) who had received biologic treatments for at least 6 months after the initial confirmed diagnosis of IBD, and with at least 3 months follow-up period after biologics discontinuation will be observed retrospectively.

Cohort 2: Participants Treated With Biologics

Participants with IBD (UC or CD) who had any dose of biologic for IBD treatment after the initial confirmed diagnosis of IBD will be observed retrospectively.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Newly diagnosed IBD participants treated with biologics including vedolizumab, adalimumab, infliximab, or golimumab will be included in this study.

You may qualify if:

• Diagnosed during February 2008 to March 2020 (or per local institutional review board \[IRB\] permitted date).
• CD (International Classification of Diseases, Ninth Revision, Clinical Modification \[ICD-9-CM\]: 555.X or International Classification of Diseases, Tenth Revision, Clinical Modification \[ICD-10-CM\]: K50.XX, K50.XXX)
• UC (ICD-9-CM: 556.X or ICD-10-CM: K51.XX, K51.XXX).
• Had received any dose of biologics for IBD treatment, including vedolizumab adalimumab, infliximab or golimumab, from February 2008 to March 2020 (or per local IRB permitted date).

You may not qualify if:

• \. Participants with any suspected diagnosis of CD or UC within one year before the initial date of confirmed IBD diagnosis will be excluded.

Sponsors & Collaborators

• Takeda: lead

Study Sites (4)

China Medical University Hospital

Taichung, 404327, Taiwan

Location

Taichung Veterans General Hospital

Taichung, 40705, Taiwan

Location

National Taiwan University Hospital

Taipei, 100229, Taiwan

Location

Chang Gung Memorial Hospital-Linkou

Taoyuan District, 333, Taiwan

Location

Related Links

• To obtain more information about this study, click this link.

MeSH Terms

Conditions

Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease

Condition Hierarchy (Ancestors)

Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases; Colitis; Colonic Diseases

Study Officials

• Study Director

  Takeda

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 24, 2022
• First Posted: October 27, 2022
• Study Start: May 27, 2021
• Primary Completion: October 27, 2022
• Study Completion: December 8, 2022
• Last Updated: January 19, 2023

Record last verified: 2023-01

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Access Criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Locations

TW (4)